Couverture de LowCarbUSA Podcast

LowCarbUSA Podcast

LowCarbUSA Podcast

De : Doug Reynolds and Pam Devine: Low Carb Podcasters
Écouter gratuitement

3 mois pour 0,99 €/mois

Après 3 mois, 9.95 €/mois. Offre soumise à conditions.

À propos de ce contenu audio

 Bringing short. positive episodes to the Low Carb community highlighting success stories from individuals and practitioners as well as tips and tricks and some great recipes.2021 LowCarbUSA® Hygiène et vie saine
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Dave Feldman on Cholesterol Code & Why the Science Isn't Settled Yet: Ep 127

      Dave Feldman on Cholesterol Code & Why the Science Isn't Settled Yet: Ep 127
      Jan 14 2026
      When Dave Feldman first walked into a LowCarbUSA® event in 2016 carrying a laptop full of lab results, few people could have predicted where that moment would lead. "I'm approaching everyone with my computer," Feldman recalls, "because I'm doing these self-experiments—getting blood work—and I'm trying to figure out why my cholesterol numbers were doing what they were doing." What started as a personal puzzle became The Cholesterol Code, a global research effort, a nonprofit scientific foundation, and now a forthcoming documentary film. In this episode of the LowCarbUSA Podcast, host Doug Reynolds sits down with Feldman to trace that journey—and to explain why the next chapter will take center stage at the Symposium for Metabolic Health in Boca Raton, January 23–25, 2026 The Question That Wouldn't Go Away Dave's original question was deceptively simple: Why do some metabolically healthy, lean people see their LDL cholesterol rise dramatically on a ketogenic diet? Over time, he noticed a consistent pattern. These individuals didn't just have high LDL—they also tended to have high HDL, low triglycerides, and excellent metabolic health. In 2017, he coined a name for this group: Lean Mass Hyper-Responders (LMHRs). But identifying a pattern wasn't enough. "Even if the lipid energy model proves correct," Dave explains, "does that mean having higher LDL on a ketogenic diet carries higher cardiovascular risk?" Answering that question required something far more difficult than a blog post or a hypothesis: a prospective imaging study. Building a Study When No One Will Fund One Dave spent years trying—and failing—to convince established institutions to study this population. "There's not a lot of funding to study metabolically healthy people with sky-high LDL," he says dryly. "The interest is usually in people who already have multiple cardiovascular risk factors—which confounds everything." So in 2019, he made a radical decision. He founded the Citizen Science Foundation, a public charity created for a single purpose: to fund independent research, with no money going to salaries or overhead. "We raised $200,000,"Dave says, "and paid a research center to do the study." By late 2021, recruitment was underway. One hundred lean, metabolically healthy ketogenic individuals underwent coronary CT angiography (CTA) scans to assess plaque in their coronary arteries, with follow-up scans roughly one year later. What the Data Actually Showed The early findings were striking. When Dave's cohort was matched against participants from the Miami Heart Study, there was no statistically significant difference in coronary plaque, despite Dave's group having LDL levels less than twice as high. "In fact," he notes, "our group trended toward lower plaque." But the most important finding emerged as more analyses were completed: "There was no association between ApoB or LDL and plaque progression," Dave says. "Whatever your LDL level was, it did not correspond with how plaque developed." What did matter? Baseline plaque. "Whether you're low-carb or not," he explains, "the more plaque you have at baseline, the more likely you are to see progression. That's consistent with the existing literature." When One Dataset Didn't Make Sense Then came the controversy. An AI-based quantitative analysis from a company called Cleerly showed plaque progression that appeared inconsistent—not only with Dave's other data, but with decades of prior research. "All of the scans showed progression," he says. "No regression. Not even noise." For an engineer, that raised immediate red flags. "If a bathroom scale is off by a quarter pound," Dave explains, "you expect wobble. Below the noise floor, measurements go up and down. But this dataset showed only one direction." Later, when Dave gained access to the anonymized data, he identified multiple anomalies and requested a blinded quality-control reanalysis. That request was declined. "I don't assume wrongdoing," he emphasizes. "But when something looks implausible, the response should be course correction." Instead, he sought independent confirmation. A second AI company, HeartFlow, conducted a fully blinded analysis—and its results aligned with every other analysis except Cleerly's. "Three out of four analyses agree," he says. "Cleerly is the outlier." Why This Matters Beyond One Study The implications extend far beyond a single dataset. Dave believes this episode exposes a deeper issue in nutrition and cardiovascular science: how dominant theories shape interpretation. "The lipid hypothesis has a gravitational pull," he says. "It affects what people expect to see—and what they question." As I put it, Dave has repeatedly taken the LowCarbUSA stage to announce findings that challenge assumptions—and each time, the conversation moves forward. "If we want better answers," Dave says, "we have to do better science." The ...
      Afficher plus Afficher moins
      33 min
    • A Cardiologist's Thoughts on the Ketogenic Diet, Heart Disease & Metabolic Health: Ep 126

      A Cardiologist's Thoughts on the Ketogenic Diet, Heart Disease & Metabolic Health: Ep 126
      Jan 11 2026
      Doug Reynolds welcomes listeners back to the LowCarbUSA® Podcast with a guest who works in one of the most specialized—and most misunderstood—corners of cardiovascular medicine: the heart's electrical system. Dr. David Nabert is an electrophysiologist ("EP" doctor), focused on heart rhythm disorders, and he's one of the featured speakers at the Boca Symposium for Metabolic Health (January 23–25)—including the event's full day-plus dedicated to cardiovascular conditions. What gives this episode its pull is the combination of clinical depth and lived experience. David isn't just talking about rhythm problems from a textbook perspective—he's explaining how his own curiosity about metabolic health evolved, what shifted when he started questioning conventional assumptions, and why those questions matter for real patients in the real world. David describes how his entry point into metabolic health didn't begin in a clinic—it began with a random Google search. In 2021, while looking up a cardiology formula, he accidentally landed on a Nina Teicholz talk at the Cato Institute. "I started to watch it, and all of a sudden, an hour and a half passed," he says—one of those moments where interest turns into momentum. He listened to Teicholz's book, The Big Fat Surprise, then began searching for more voices in the low-carb space and quickly reconnected with familiar names, including Dr. Robert Cywes and Dr. Eric Westman (both will also be presenting in Boca), whom he calls mentors. That exploration ultimately led him to the Society of Metabolic Health Practitioners (The SMHP) and, importantly, a willingness to test ideas on himself. David is candid about his own weight journey. He describes a time when a body mass index under 25 felt "skinny" to him, and he's open about losing weight, regaining some after a series of hip surgeries, and continuing to work on it. What ultimately shifted, though, wasn't just the number on the scale—it was how he began to rethink what "doing everything right" actually means. For years, he approached weight loss the way many clinicians were trained to: low-fat, high willpower, endure the hunger. He describes his old strategy bluntly: "The only way I had lost weight… was by doing protein sparing modified fast… I was just eating almost no fat." Predictably, it wasn't sustainable. When he later shifted to a lower-carb, higher-fat approach—"bacon, eggs, hamburger"—he was "amazed at how quickly I started to lose weight," and he began seeing changes in markers that traditional cardiology often de-emphasizes. After stopping long-term statin therapy (which he had been on for 25 years), he saw his LDL return to roughly where it had been earlier in life, but other changes caught his attention: triglycerides dropped to the lowest he'd ever seen, HDL improved, and fasting insulin improved as well. Just as meaningful were the changes he felt: "Every 10 or 20 pounds I lost, my hips got better," he says, attributing it not only to less load, but "also part of it was less inflammation." From there, the episode moves into the heart of why David is speaking during the cardiovascular-focused programming in Boca: rhythm, electricity, and the surprising overlap between conditions that seem unrelated—like seizures and arrhythmias. David explains that early ketogenic diet research in the 1920s focused on refractory seizures, and he argues the connection matters because many antiarrhythmic drugs and antiseizure drugs overlap mechanistically. In his view, these aren't separate worlds. "Treating seizures or treating cardiac arrhythmias is basically two faces of the same coin," he says—and that opens a practical question: if ketosis can help reduce seizures, might it also influence certain rhythm symptoms? He shares a striking clinical example that stuck with him: a former submariner with PTSD and episodes of fast heart rates who said, "I know when I'm… ketogenic… when I fall off the wagon… then I start having palpitations and fast heart rates." David later learned the patient was experiencing atrial fibrillation, and while he's careful not to overpromise, he describes a pattern he's observed: in earlier stages of rhythm problems, being in a ketogenic state may reduce symptoms and potentially slow progression for some people. "It doesn't cure atrial fibrillation," he emphasizes, but he's seen ketosis "improves symptoms," not only in AFib, but in other rhythm issues like SVT and PVCs—especially early on. From there, David widens the frame to what he's seeing in younger patients—particularly young women—showing up with palpitations, rapid heart rate, anxiety, and signs of metabolic dysfunction even when they don't "look" unhealthy by BMI alone. "Only 90% of them are metabolically unhealthy," he says, describing a familiar cluster: A1C not quite normal, resting heart rates high, daytime heart rates that shouldn't be running 100–120, and a nervous system dialed up in what ...
      Afficher plus Afficher moins
      53 min
    • The SMHP Research Academy, an introduction with Dr. Melanie Tidman

      The SMHP Research Academy, an introduction with Dr. Melanie Tidman
      Nov 21 2025
      Inside the SMHP Research Academy: How Practitioners Can Turn Real-World Results Into Published Science

      When the Society of Metabolic Health Practitioners (SMHP) launched the Journal of Metabolic Health in late 2023, one question quickly rose to the surface: How do we help frontline clinicians, many of whom have never conducted research, learn to design, run, and publish high-quality studies?

      Enter Dr. Melanie Tidman.

      A professor, researcher, and longtime SMHP member, Melanie recognized a gap, and built a solution. The result is the SMHP Research Academy, a fully supported, step-by-step pathway that teaches practitioners how to take research ideas from concept to publication. In this podcast episode, she walks listeners through what the Academy offers, why it exists, and how it's already helping clinicians produce peer-reviewed science.

      Below is a summary of what you'll hear, but the full interview is worth every minute.

      A One-of-a-Kind Resource for Practitioners

      Melanie created the Academy in early 2024 with a clear mission: make research accessible to clinicians working in the real world.

      "I had the vision back then to create an academy where our members who have never done research before could learn all of the ins and outs… of how to do research, how to collect data, how to analyze that data and how to publish a research article."

      Over nine months she built a 10-module, self-paced research curriculum, complete with video lessons, customizable learning formats, downloadable notes, and direct faculty support. Members can take the modules in order or revisit individual sections as needed.

      Each module, she notes, is "completely comprehensive and customizable for your own learning style."

      IRB Support—Including Up to $3,000 in Savings

      One of the biggest hurdles for new researchers is the IRB (Institutional Review Board) process. It's required for human studies in the U.S., but few practitioners know how to navigate it, and few are aware that approval often costs between $1,500 and $3,000.

      Melanie explains the differences between exempt, expedited, and full-board studies and then shares the Academy's unique advantage:

      "Two of us on the academy faculty are also faculty for universities having access to university IRBs… we become the primary investigator for the purpose of the IRB application… and there is no cost."

      For members, that alone is a major benefit—one of many.

      Faculty-Guided Support From Design to Publication

      The Academy pairs each participant with a research mentor and faculty team specializing in study design, data analysis, manuscript writing, and qualitative methods. Projects now include case reports, retrospective analyses, literature reviews, mixed-methods studies, and more.

      As Melanie notes, the Academy already has 16 projects underway, including "three articles in peer review right now."

      She emphasizes that no project is too small: "Say you just have one patient who had an incredible result, and you want to publish… I'm your man."

      Up to $10,000 in Total Value—Free for SMHP Members

      When Melanie adds up the typical costs—IRB fees, data-analysis consultation, manuscript editing, and open-access publication fees—she estimates that members receive between $9,000 and $10,000 worth of services at no charge.

      "If you publish with the Journal of Metabolic Health and you are a member of the SMHP, the SMHP will pay your open-access publishing fees," she explains. "There's another three to four thousand dollars worth of savings."

      Why This Matters

      The Academy empowers clinicians, from solo practitioners to large-system physicians, to turn real-world metabolic health outcomes into peer-reviewed evidence. And as Melanie reminds listeners:

      "I can't say enough about my gratitude… It's there for your benefit. If you are a member, you have an entire Academy worth of information at your fingertips."

      Learn more about The SMHP™ and join here.
      Afficher plus Afficher moins
      31 min
    Aucun commentaire pour le moment